

Regulatory Story

[Go to market news section](#)



Cathay International Holdings Ld - CTI Lansen reports interim results
Released 14:28 28-Aug-2018

RNS Number : 0325Z
Cathay International Holdings Ld
28 August 2018

Cathay International Holdings Limited ("Cathay" or the "Company" or together with its subsidiaries, the "Group")

Lansen reports interim results for the six months ended 30 June 2018

Hong Kong, 28 August 2018 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"), today notes Lansen Pharmaceutical Holdings Ltd ("**Lansen**") (HKEX: 503), the Company's 50.56% owned subsidiary, has reported its interim results for the six months ended 30 June 2018 in accordance with the requirements of its Hong Kong listing.

The full text of the Lansen Announcement can be found at <http://www.hkexnews.hk/listedco/listconews/sehk/2018/0828/LTN201808281039.pdf> and will also be made available at Announcements & Notices section of Lansen's homepage at <http://holding.lansen.com.cn/en/newslst.aspx?NodeCode=10002000700050005>.

As previously announced, Cathay will issue its Interim Results for the six months ended 30 June 2018 on Friday 31 August 2018.

-Ends-

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

Tel: +852 2828 9289

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

Tel: +44 (0) 203 709 5702

About Cathay

Cathay International Holdings Limited (LSE: CTIL) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DOCPGUCPRUPRGWR

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

Lansen reports interim results - RNS